Avicanna Inc. (TSX:AVCN)
0.1300
0.00 (0.00%)
Aug 28, 2026, 9:11 AM EST
Avicanna Revenue
Avicanna had revenue of 5.64M CAD in the quarter ending June 30, 2026, a decrease of -8.45%. This brings the company's revenue in the last twelve months to 25.31M, down -0.23% year-over-year. In the year 2025, Avicanna had annual revenue of 25.48M with 0.08% growth.
Revenue (ttm)
25.31M
Revenue Growth
-0.23%
P/S Ratio
0.71
Revenue / Employee
226.02K
Employees
112
Market Cap
17.90M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 25.48M | 19.48K | 0.08% |
| Dec 31, 2024 | 25.46M | 8.67M | 51.62% |
| Dec 31, 2023 | 16.79M | 12.74M | 314.82% |
| Dec 31, 2022 | 4.05M | 778.98K | 23.83% |
| Dec 31, 2021 | 3.27M | 1.70M | 108.20% |
| Dec 31, 2020 | 1.57M | 1.40M | 833.16% |
| Dec 31, 2019 | 168.25K | 50.28K | 42.62% |
| Dec 31, 2018 | 117.97K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Ayr Wellness | 650.97M |
| iAnthus Capital Holdings | 197.59M |
| Red White & Bloom Brands | 59.58M |
| MediPharm Labs | 41.46M |
| Avant Brands | 33.64M |
| Medicure | 32.08M |
| Greenway Greenhouse Cannabis | 7.45M |
| PharmaCielo | 2.54M |
Avicanna News
- 11 days ago - Avicanna Announces Closing of Strategic Non-Brokered Private Placement - GlobeNewsWire
- 16 days ago - Avicanna Registration statement: Q2 2026 - Filings
- 16 days ago - Avicanna Registration statement: Q2 2026 - Filings
- 16 days ago - Avicanna Earnings release: Q2 2026 - Filings
- 16 days ago - Avicanna Reports Q2 2026 Financial Results - GlobeNewsWire
- 6 weeks ago - Avicanna Introduces QUIX™ Rapid-Onset Medical Cannabis Portfolio - GlobeNewsWire
- 2 months ago - Avicanna Announces Promotion of Nick Hilborn CPA CA to Chief Financial Officer - GlobeNewsWire
- 2 months ago - Splash Beverage Group Invests in Avicanna, a Leading Cannabinoid Biopharmaceutical Platform, Advancing Its Transformation Into Cannabinoid Healthcare - GlobeNewsWire